|
Home
What is
Hepatitis
How is it
Transmitted
Long Term
Prognosis
Complications of
HCV
Liver
Biopsy
Treatment Info
(Interferon, Herbal, etc)
Lab Tests (PCR,
Genotype,etc.)
Nutrition
& Alternative Info
Patient
Information (Support Groups, Doctor Listing,
etc)
Related
Webpages
Transplant
Info
HCV
Webrings
My
guestbookbook
Site
Awards
FAQ &
Disclaimers
|
TITLE: Effect of Interferon Therapy on
Hepatocellular Carcinogenesis in Patients With Chronic Hepatitis
Type C: A Long-Term Observation Study of 1,643 Patients Using
Statistical Bias Correction With Proportional Hazard Analysis.
The activity of interferon (IFN) is not elucidated from the
viewpoint of cancer prevention in chronic hepatitis C patients en
masse. The hepatocellular carcinogenesis rate was analyzed
statistically in 1,643 patients with chronic hepatitis C: 1,191
patients with IFN therapy and 452 without IFN therapy.
Hepatocellular carcinogenesis rates in the treated and untreated
groups were 2.1% and 4.8% at the end of the 5th year, and 7.6% and
12.4% at the 10th year, respectively (P =.0036). Multivariate
analysis showed that IFN slightly decreased the risk of
carcinogenesis by 33%, compared with that of untreated patients (P
=.14), adjusting for the confounding effects of age, fibrotic
stage, gender, and gamma-glutamyl transpeptidase (GGTP) value.
Among 1,191 patients with IFN, 461 patients attained persistent
loss of hepatitis C virus (HCV) RNA, and the other 145 patients
retained normal alanine transaminase (ALT) values without loss of
HCV RNA. The hazard of carcinogenesis in these 606 patients with
persistent normal ALT with or without HCV-RNA clearance was
significantly lower than that of untreated patients (hazard ratio:
0.32; P =.012) and that of the abnormal aminotransferase group.
Among patients with chronic hepatitis C, IFN significantly
decreased the hepatocellular carcinogenesis rate in those patients
with normal or persistent low ALT values.
AUTHOR: Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y,
Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H,
Kawanishi M, Department of Gastroenterology, Toranomon Hospital,
Tokyo, and Okinaka Memorial Institute for Medical Research, Tokyo,
Japan.
SOURCE: Hepatology 1999 Apr;29(4):1124-1130
Home | What is HCV | Transmission |
Future |
Complications |
Biopsy |
Treatment
| Lab |
Nutrition |
Patient |
Links | Transplant |
Webrings |
guestbookbook |
Awards |
FAQ
|
|